CAS: 287714-41-4; (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-Isopropyl-2-(N-Methylmethylsulfonamido)Pyrimidin-5-yl)-3,5-Dihydroxyhept-6-Enoic Acid

该化合物是一种合成脂质低耗剂,主要用于管理高脂性贫血和减少心血管疾病的风险.其化学配方为C22H28 FF3O6S,其特点是一种独特的结构,包括含氟苯基和磺酰胺杂醇,有助于其发芽.Rosuvastatin功能抑制了HMG-CoA再生酶,这是一种对肝脏胆固醇生物合成至关重要的酶,从而降低了低密度脂蛋白素(LDL)胆固醇和三甘甘油的含量,同时增加了高密度脂质(HDL)胆固醇(Choolesterol),其特征是高生物利用率和长半衰期,允许一次性服用.它一般都受到很好的刺激,但潜在的副作用可能包括肌肉疼痛,肝酶增生和胃肠道扰动.Rosustastetin经常与生活方式的改变相结合,如饮食和运动中广泛使用其安全性能和运动,以提高其药质的安全性.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid methyl ester (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidine-5-yl]-3,5-dihydroxyhept-6-enoic acid isopropylamine rosuvastatin tert-butyl ester rosuvastatin methylamine salt(+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-heptenoic acid cyclohexylammonium salt (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidine-5-yl]-3,5-dihydroxyhept-6-enoic acid isopropylamine (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-heptenoic acid tert-°Ctylammonium salt dehydroabietylamine salt of rosuvastatin

合成工艺路线路线简述

    (3R,5S,6E)-7-[4-(4-Fluorophenyl)-2-(N-Methylmethanesulfonamido)-6-(Isopropyl)Pyrimidine-5-Yl]-3,5-Dihydroxyhept-6-Enoic Acid Isopropylamine置于sodium Hydroxide,水体系中,用 乙醇 用作溶剂,化学反应 2.0H,反应生成罗伐他汀
    参考文献: Crystalline Ammonium Salts Of Rosuvastatin[fr] Sels D'Ammonium Cristallins De La Rosuvastatine
    标题: Crystalline Ammonium Salts Of Rosuvastatin[fr] Sels D'Ammonium Cristallins De La Rosuvastatine
    摘要:提供的是罗伐他汀的烷基铵晶体盐,可用于纯化罗伐他汀及其药用可接受盐.

    海关参考信息

    专利信息


    专利号:US-8269001-B2
    优先权日:2005-10-05
    标题 :Process for the synthesis of HMG-CoA reductase inhibitors
    发明人:CASAR ZDENKO
    权利人:CASAR ZDENKO; LEK PHARMACEUTICALS
    摘要:A novel synthesis of statins uses Wittig reaction of a heterocyclic core of statin with a lactonized side chain already possessing needed stereochemistry. Any separation of diastereoisomers is performed early in the course of synthesis.

    专利号:WO-2014140006-A1
    优先权日:2013-03-11
    标 题:Process for enantioselective synthesis of 3-hydroxy-glutaric acid monoesters and use thereof
    发明人:KÖNIG BURGHARD; WETTERICH FRANK; GRÖGER HARALD; METZNER RICHARD
    权利人:SANDOZ AG; UNIVERSITÄT BIELEFELD
    摘要:The present invention relates to a process for the enzymatic enantioselective synthesis of 3-hydroxy- glutaric acid esters of formula 1 with R 1 being alkyl, aryl, or substituted alkyl, as well as the use compounds of formula 1 in the synthesis.

    专利号:US-9085538-B2
    优先权日:2010-07-26
    标题:Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
    发明人:CASAR ZDENKO; STERK DAMJAN; JUKIC MARKO
    权利人:CASAR ZDENKO; STERK DAMJAN; JUKIC MARKO; LEK PHARMACEUTICALS
    摘要:The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.

    专利号:US-10005720-B2
    优先权日:2013-04-05
    标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
    发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
    权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
    摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

    专利号:EP-2017267-A1
    优先权日:2007-07-16
    标 题:Synthesis of statins
    发明人:KOPITAR GREGOR; MRAK PETER; OSLAJ MATEJ
    权利人:LEK PHARMACEUTICALS
    摘要:The process for synthesis of statins is presented where the intermediate intermediate (4 R ,6 S )-6-(dialkoxymethyl)tetrahydro-2 H -pyran-2,4-diol which already possesses the desired stereochemistry corresponding to final statin is prepared by an aldolaze.

    专利号:US-10173993-B2
    优先权日:2015-12-09
    标题 :Process for the synthesis of sulfones and sulfonamides
    发明人:VON WOLFF NIKLAS; CHAR JOËLLE; CANTAT THIBAULT
    权利人:COMMISSARIAT ENERGIE ATOMIQUE
    摘要:A one pot single step process is described for the synthesis of a compound, including a labeled compound, containing a sulfonyl functional group comprising the step of mixing together a silane, an SO 2 source, an electrophilic compound, an activating compound and optionally a metal catalyst. A process for producing tracers from a labeled sulfonyl containing compound prepared by the described process is also included.
    江西埃菲姆科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.afmpharm.com/
    电话: 793-33899567 13735087952👤
    📞江西埃菲姆科技有限公司 ⚠️参考联系方式

    销售电话:793-33899567 13735087952
    邮箱:sales@afmpharm.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    北京世纪迈劲生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.mediking.cn
    企业联系电话:010-81769521👤
    📞北京世纪迈劲生物科技有限公司 ⚠️参考联系方式
    联系人:高经理
    电话:010-81769521
    手机:15901403431
    传真:010-81769652
    邮箱:sales@mediking.cn
    通信地址: 北京市亦庄经济技术开发区永昌中路甲6号院A座4层
    邮编: 100176
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:北京市亦庄经济技术开发区永昌中路甲6号院A座4层
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    江西埃菲姆药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.afmpharm.com
    企业联系电话:0570-6040288👤
    📞江西埃菲姆药业有限公司 ⚠️参考联系方式
    联系人:董经理
    电话:0570-6040288
    手机:13320031450
    传真:86-570-6259526
    邮箱:sales@afmpharm.com
    通信地址: 江西省万年县石镇工业园区
    邮编: 324000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江西省万年县石镇工业园区
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Li M, Noordam R, Trompet S, Winter EM, Jukema JW, Arbous MS, Rensen PCN, Kooijman S. The impact of statin use on sepsis mortality. J Clin Lipidol. 2024 Jul
    27:S1933-2874(24)00215-0. doi: 10.1016/j.jacl.2024.07.006. Epub ahead of print. 72(9):64-72. doi: 10.59556/japi.72.0622.
    325:125123. doi: 10.1016/j.saa.2024.125123. Epub ahead of print.

    合成参考文献


    摘要:Kleemann A; Cardiovascular Drugs. Ullmann's Encyclopedia of Industrial Chemistry 7th ed. (1999-2017). NY, NY: John Wiley & Sons. Online Posting Date: January 15, 2008
    摘要:American Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 1867
    摘要:Sigma-Aldrich; Safety Data Sheet for Rosuvastatin calcium. Product Number: SML1264, Version 5.0 (Revision Date 04/23/2015). Available from, as of January 19, 2017:
    摘要:Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 7-4, 7-5, 8-12 (1990)
    摘要:Franke C et al; Chemosphere 29: 1501-14 (1994)
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知